Security Snapshot

BeOne Medicines Ltd. - Ordinary Shares, par value $0.0001 per share (ONC) Institutional Ownership

CUSIP: 07725L102

13F Institutional Holders and Ownership History from Q1 2016 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

281

Shares (Excl. Options)

33,815,427

Price

$303.81

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Ordinary Shares, par value $0.0001 per share
Symbol
ONC on Nasdaq
Shares outstanding
1,448,978,913
Price per share
$296.97
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
33,815,427
Total reported value
$10,272,310,792
% of total 13F portfolios
0%
Share change
+722,685
Value change
+$214,390,087
Number of holders
281
Price from insider filings
$296.97
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • ONC - BeOne Medicines Ltd. - Ordinary Shares, par value $0.0001 per share is tracked under CUSIP 07725L102.
  • 281 institutions reported positions in Q4 2025.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 281 to 59 between Q4 2025 and Q1 2026.
  • Reported value moved from $10,272,310,792 to $169,478,574.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 281 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 07725L102?
CUSIP 07725L102 identifies ONC - BeOne Medicines Ltd. - Ordinary Shares, par value $0.0001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of BeOne Medicines Ltd. - Ordinary Shares, par value $0.0001 per share (ONC) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BAKER BROS. ADVISORS LP 8% $34,424,296,187 115,918,313 Julian C. Baker 16 Apr 2026
HHLR ADVISORS, LTD. 4.9% -26% $16,788,174,431 -$5,939,951,540 68,551,141 -26% HHLR Advisors, Ltd. 09 May 2025

As of 31 Dec 2025, 281 institutional investors reported holding 33,815,427 shares of BeOne Medicines Ltd. - Ordinary Shares, par value $0.0001 per share (ONC). This represents 2.3% of the company’s total 1,448,978,913 outstanding shares.

Institutional Holders of BeOne Medicines Ltd. - Ordinary Shares, par value $0.0001 per share (ONC) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 570,744 $169,478,574 +$16,799,754 $296.97 59
2025 Q4 33,815,427 $10,272,310,792 +$214,390,087 $303.81 281
2025 Q3 32,958,063 $11,226,015,297 -$346,958,018 $340.70 261
2025 Q2 34,445,503 $8,338,029,358 -$2,097,913,474 $242.07 240
2025 Q1 42,522,929 $11,571,304,178 -$300,776,021 $272.17 260
2024 Q4 43,668,178 $8,065,581,343 -$576,365,574 $184.71 222
2024 Q3 46,519,526 $10,440,141,817 -$116,771,313 $224.51 221
2024 Q2 46,804,066 $6,679,478,929 +$49,458,709 $142.67 195
2024 Q1 46,433,670 $7,261,664,670 +$228,390,098 $156.39 198
2023 Q4 44,965,141 $8,109,589,388 -$358,939,167 $180.36 201
2023 Q3 46,934,356 $8,443,617,070 -$8,576,628 $179.87 195
2023 Q2 47,044,110 $8,388,424,595 -$134,114,517 $178.30 200
2023 Q1 47,729,619 $10,288,729,347 -$365,549,782 $215.53 214
2022 Q4 49,411,792 $10,871,665,562 -$822,129,900 $219.94 206
2022 Q3 53,491,519 $7,213,600,064 -$18,667,417 $134.82 204
2022 Q2 53,542,991 $8,666,746,485 -$222,094,321 $161.85 217
2022 Q1 54,923,857 $10,369,831,154 -$143,839,726 $188.60 228
2021 Q4 55,475,829 $15,026,076,469 -$242,691,110 $270.93 247
2021 Q3 56,111,399 $20,367,209,544 +$187,897,220 $363.00 242
2021 Q2 55,478,557 $19,043,602,189 -$143,508,273 $343.19 259
2021 Q1 55,905,428 $19,451,416,879 +$655,221,281 $348.08 241
2020 Q4 54,296,531 $14,026,755,839 -$183,663,940 $258.39 234
2020 Q3 54,822,916 $15,700,067,419 +$1,338,448,467 $286.44 238
2020 Q2 50,121,058 $9,441,745,077 +$213,639,854 $188.40 209
2020 Q1 48,964,204 $6,027,968,489 -$8,363,206 $123.11 205
2019 Q4 48,934,325 $8,110,832,589 -$138,704,780 $165.76 217
2019 Q3 49,991,082 $6,121,591,847 +$324,001,095 $122.46 192
2019 Q2 49,119,839 $6,088,356,127 +$19,061,884 $123.95 196
2019 Q1 46,975,583 $6,199,612,280 +$70,636,203 $132.00 193
2018 Q4 47,454,252 $6,654,826,169 -$438,071,948 $140.26 188
2018 Q3 45,496,681 $7,835,602,804 +$598,946,530 $172.22 142
2018 Q2 42,212,313 $6,489,342,702 +$892,872,904 $153.73 128
2018 Q1 36,449,398 $6,123,436,880 +$1,501,911,684 $168.00 122
2017 Q4 27,567,001 $2,693,889,000 +$229,200,708 $97.72 93
2017 Q3 25,192,357 $2,606,391,144 +$502,359,860 $103.46 81
2017 Q2 20,400,002 $917,998,000 +$131,190,803 $45.00 57
2017 Q1 17,607,585 $644,614,000 +$43,545,126 $36.61 54
2016 Q4 16,604,419 $504,116,000 +$195,354,542 $30.36 54
2016 Q3 10,161,007 $313,122,000 +$58,302,863 $30.81 38
2016 Q2 8,275,591 $241,301,000 +$16,647,965 $29.80 39
2016 Q1 7,721,859 $221,022,000 +$221,022,000 $29.31 40
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .